Cargando…

The Clinical Utility of Salivary Biomarkers in the Identification of Type 2 Diabetes Risk and Metabolic Syndrome

Type 2 diabetes is traditionally diagnosed by the use of an oral glucose tolerance test and/or HbA1c, both of which require serum collection. Various biomarkers, which are measurable biological substances that provide clinical insight on disease state, have also been effective in the early identific...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Priya, Donovan, Lorin, Janowitz, Elizabeth, Kim, Joon Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553598/
https://www.ncbi.nlm.nih.gov/pubmed/33116710
http://dx.doi.org/10.2147/DMSO.S265879
_version_ 1783593636378705920
author Desai, Priya
Donovan, Lorin
Janowitz, Elizabeth
Kim, Joon Young
author_facet Desai, Priya
Donovan, Lorin
Janowitz, Elizabeth
Kim, Joon Young
author_sort Desai, Priya
collection PubMed
description Type 2 diabetes is traditionally diagnosed by the use of an oral glucose tolerance test and/or HbA1c, both of which require serum collection. Various biomarkers, which are measurable biological substances that provide clinical insight on disease state, have also been effective in the early identification and risk prediction of inflammatory diseases. Measuring biomarker concentrations has traditionally been obtained through serum collection as well. However, numerous biomarkers are detectable in saliva. Salivary analysis has more recently been introduced into research as a potential non-invasive, cost-effective diagnostic for the early identification of type 2 diabetes risk in adults and youth. Therefore, the purpose of this review was to compare 6 established inflammatory biomarkers of type 2 diabetes, in serum and saliva, and determine if similar diagnostic effectiveness is seen in saliva. A lack of standardized salivary analysis, processing, and collection accounts for errors and inconsistencies in conclusive data amongst studies. Proposing a national standardization in salivary analysis, coupled with increased data and research on the utility of saliva as a diagnostic, poses the potential for salivary analysis to be used in diagnostic settings.
format Online
Article
Text
id pubmed-7553598
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-75535982020-10-27 The Clinical Utility of Salivary Biomarkers in the Identification of Type 2 Diabetes Risk and Metabolic Syndrome Desai, Priya Donovan, Lorin Janowitz, Elizabeth Kim, Joon Young Diabetes Metab Syndr Obes Review Type 2 diabetes is traditionally diagnosed by the use of an oral glucose tolerance test and/or HbA1c, both of which require serum collection. Various biomarkers, which are measurable biological substances that provide clinical insight on disease state, have also been effective in the early identification and risk prediction of inflammatory diseases. Measuring biomarker concentrations has traditionally been obtained through serum collection as well. However, numerous biomarkers are detectable in saliva. Salivary analysis has more recently been introduced into research as a potential non-invasive, cost-effective diagnostic for the early identification of type 2 diabetes risk in adults and youth. Therefore, the purpose of this review was to compare 6 established inflammatory biomarkers of type 2 diabetes, in serum and saliva, and determine if similar diagnostic effectiveness is seen in saliva. A lack of standardized salivary analysis, processing, and collection accounts for errors and inconsistencies in conclusive data amongst studies. Proposing a national standardization in salivary analysis, coupled with increased data and research on the utility of saliva as a diagnostic, poses the potential for salivary analysis to be used in diagnostic settings. Dove 2020-10-09 /pmc/articles/PMC7553598/ /pubmed/33116710 http://dx.doi.org/10.2147/DMSO.S265879 Text en © 2020 Desai et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Desai, Priya
Donovan, Lorin
Janowitz, Elizabeth
Kim, Joon Young
The Clinical Utility of Salivary Biomarkers in the Identification of Type 2 Diabetes Risk and Metabolic Syndrome
title The Clinical Utility of Salivary Biomarkers in the Identification of Type 2 Diabetes Risk and Metabolic Syndrome
title_full The Clinical Utility of Salivary Biomarkers in the Identification of Type 2 Diabetes Risk and Metabolic Syndrome
title_fullStr The Clinical Utility of Salivary Biomarkers in the Identification of Type 2 Diabetes Risk and Metabolic Syndrome
title_full_unstemmed The Clinical Utility of Salivary Biomarkers in the Identification of Type 2 Diabetes Risk and Metabolic Syndrome
title_short The Clinical Utility of Salivary Biomarkers in the Identification of Type 2 Diabetes Risk and Metabolic Syndrome
title_sort clinical utility of salivary biomarkers in the identification of type 2 diabetes risk and metabolic syndrome
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553598/
https://www.ncbi.nlm.nih.gov/pubmed/33116710
http://dx.doi.org/10.2147/DMSO.S265879
work_keys_str_mv AT desaipriya theclinicalutilityofsalivarybiomarkersintheidentificationoftype2diabetesriskandmetabolicsyndrome
AT donovanlorin theclinicalutilityofsalivarybiomarkersintheidentificationoftype2diabetesriskandmetabolicsyndrome
AT janowitzelizabeth theclinicalutilityofsalivarybiomarkersintheidentificationoftype2diabetesriskandmetabolicsyndrome
AT kimjoonyoung theclinicalutilityofsalivarybiomarkersintheidentificationoftype2diabetesriskandmetabolicsyndrome
AT desaipriya clinicalutilityofsalivarybiomarkersintheidentificationoftype2diabetesriskandmetabolicsyndrome
AT donovanlorin clinicalutilityofsalivarybiomarkersintheidentificationoftype2diabetesriskandmetabolicsyndrome
AT janowitzelizabeth clinicalutilityofsalivarybiomarkersintheidentificationoftype2diabetesriskandmetabolicsyndrome
AT kimjoonyoung clinicalutilityofsalivarybiomarkersintheidentificationoftype2diabetesriskandmetabolicsyndrome